Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of the American College of Cardiology (JACC)
Patients on rilonacept experienced more days with no or minimal pericarditis symptoms (81% vs. 25%; p < 0.001) and more persistent clinical response at 16 weeks (81% vs. 20%; p < 0.001) compared with placebo.
Cardiology September 15th 2025
CMR-guided therapeutic approach decreased rates of recurrence, exposure to glucocorticoids, and pericardiocentesis, demonstrating measurable practice improvements.
Cardiology Advisor
Compared with patients who experience a single episode of pericarditis, those with recurrent disease are more likely to experience complications such as pericardial effusion or tamponade.
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS